NTRK1 and diffuse large B-cell lymphoma: Notably, pan-pharmacological inhibition of TRKs enhanced sensitivity of diffuse large B-cell lymphoma (DLBCL) to the monoclonal antibody against CD20 rituximab 45, whereas treatment with NGF protected TRKA-transformed myeloid 32D cells against irradiation 46.